Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 2
2024 54
2025 73
2026 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Results by year

Filters applied: . Clear all
Page 1
Waldenstrom Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management.
Gertz MA. Gertz MA. Am J Hematol. 2025 Jun;100(6):1061-1073. doi: 10.1002/ajh.27666. Epub 2025 Mar 17. Am J Hematol. 2025. PMID: 40095219 Review.
DISEASE OVERVIEW: Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. ...
DISEASE OVERVIEW: Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal pr …
Diagnosis and Management of Waldenstrom's Macroglobulinemia.
Treon SP, Sarosiek S, Castillo JJ. Treon SP, et al. Hematol Oncol. 2025 Jun;43 Suppl 2:e70071. doi: 10.1002/hon.70071. Hematol Oncol. 2025. PMID: 40517545 Review.
Waldenstrom macroglobulinemia (WM) is an IgM secreting lymphoplasmacytic lymphoma. Mutations in MYD88 (95%-97%) and CXCR4 (30%-40%) are common in patients with WM. ...
Waldenstrom macroglobulinemia (WM) is an IgM secreting lymphoplasmacytic lymphoma. Mutations in MYD88 (95%-97%) and CXCR4 (30% …
Monoclonal Gammopathy-Associated Neuropathy.
Sarosiek S, Doughty CT, Castillo JJ. Sarosiek S, et al. Curr Hematol Malig Rep. 2024 Dec 16;20(1):2. doi: 10.1007/s11899-024-00745-8. Curr Hematol Malig Rep. 2024. PMID: 39680359 Review.
PURPOSE OF REVIEW: Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with an IgM monoclonal gammopathy or Waldenstrom macroglobulinemia. RECENT FINDINGS: There are multiple potential ways that the pa …
PURPOSE OF REVIEW: Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with …
Diagnosis and Risk Stratification in Waldenstrom Macroglobulinemia.
Zanwar S, Kapoor P. Zanwar S, et al. J Natl Compr Canc Netw. 2024 Sep;22(7):e247024. doi: 10.6004/jnccn.2024.7024. J Natl Compr Canc Netw. 2024. PMID: 39236757 Review.
Waldenstrom macroglobulinemia (WM) is a B-cell lymphoma characterized by the presence of bone marrow lymphoplasmacytic infiltration and circulating monoclonal immunoglobulin M protein. ...
Waldenstrom macroglobulinemia (WM) is a B-cell lymphoma characterized by the presence of bone marrow lymphoplasmacytic infiltr …
BTK inhibitors in CLL: second-generation drugs and beyond.
Tam C, Thompson PA. Tam C, et al. Blood Adv. 2024 May 14;8(9):2300-2309. doi: 10.1182/bloodadvances.2023012221. Blood Adv. 2024. PMID: 38478390 Free PMC article. Review.
BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia. The first-generation BTKi ibrutinib demonstrated superiority over standard chemo …
BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell …
Optimizing BTK Inhibition in Waldenstrom Macroglobulinemia.
Sarosiek S, Castillo JJ. Sarosiek S, et al. J Natl Compr Canc Netw. 2024 May;22(4):e247007. doi: 10.6004/jnccn.2024.7007. J Natl Compr Canc Netw. 2024. PMID: 38754469 Review.
Bruton tyrosine kinase (BTK) inhibitors have become a standard of care in the treatment of patients with Waldenstrom macroglobulinemia (WM) and are the only medications approved by the FDA to treat these patients. ...
Bruton tyrosine kinase (BTK) inhibitors have become a standard of care in the treatment of patients with Waldenstrom macroglobulin …
Inflammatory Waldenstrom macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort.
Debureaux PE, Poulain S, Harel S, Passet M, Templé M, Friedrich C, Forgeard N, Elessa D, Plas W, Chat L, Lazarian G, Willems L, Royer B, Talbot A, Vaugeois T, Theves F, Terré A, Brignier A, Malphettes M, Krzisch D, Frenzel L, Davi F, Bravetti C, Nguyen-Khac F, Dupuis J, Cuccuini W, Bouscary D, Hermine O, Roos-Weil D, Kosmider O, Clappier E, Espéli M, Balabanian K, Arnulf B. Debureaux PE, et al. Blood. 2025 Jan 23;145(4):450-454. doi: 10.1182/blood.2024025738. Blood. 2025. PMID: 39571148 Free article.
Inflammatory form of Waldenstrom macroglobulinemia (iWM) predicts outcomes after immuno-chemotherapy and Bruton tyrosine kinase inhibitors, but its origin is unknown. ...
Inflammatory form of Waldenstrom macroglobulinemia (iWM) predicts outcomes after immuno-chemotherapy and Bruton tyrosine kinas …
Zanubrutinib in the treatment of Waldenstrom Macroglobulinemia.
Goodall E, Opat S. Goodall E, et al. Future Oncol. 2025 Oct;21(24):3151-3158. doi: 10.1080/14796694.2025.2558351. Epub 2025 Sep 11. Future Oncol. 2025. PMID: 40932034 Free PMC article. Review.
Waldenstrom Macroglobulinemia (WM) is an uncommon malignancy of IgM-secreting lymphoplasmacytic cells. ...
Waldenstrom Macroglobulinemia (WM) is an uncommon malignancy of IgM-secreting lymphoplasmacytic cells. ...
Current and emerging treatment perspectives for adults with Waldenstrom macroglobulinemia.
Guijosa A, Sarosiek S, Castillo JJ. Guijosa A, et al. Expert Rev Anticancer Ther. 2025 May;25(5):485-497. doi: 10.1080/14737140.2025.2488312. Epub 2025 Apr 3. Expert Rev Anticancer Ther. 2025. PMID: 40176471 Review.
INTRODUCTION: Waldenstrom Macroglobulinemia (WM) is distinguished from other indolent lymphomas by its unique molecular landscape and clinical behavior. ...
INTRODUCTION: Waldenstrom Macroglobulinemia (WM) is distinguished from other indolent lymphomas by its unique molecular landsc …
129 results